72_CD Company_NN information_NN and_CC advisers_NNS COMPANY_NNP SECRETARY_NNP ,_, REGISTERED_NNP OFFICE_NNP AND_CC GROUP_NNP HEADQUARTERS_NNPS ANNOUNCEMENTS_NNPS Elizabeth_NNP Brown_NNP First_NNP quarter_NN results_NNS May_MD Peterhouse_NNP Technology_NNP Park_NNP Second_NNP quarter_NN interim_JJ results_NNS September_NNP 100_CD Fulbourn_NNP Road_NNP Third_NNP quarter_NN results_NNS November_NNP Cambridge_NNP CB1_NNP 9PT_NNP ,_, UK_NNP Final_NNP results_NNS March_NNP Telephone_NNP 44_CD 0_CD 1223 275 300_CD CORPORATE_JJ ADVISERS_NNS Registered_NNP number_NN 2863682_CD Legal_NNP advisers_NNS Date_NNP of_IN incorporation_NN 19_CD October_NNP 1993_CD Weil_NNP ,_, Gotshal_NNP &_CC Manges_NNP Country_NNP of_IN jurisdiction_NN England_NNP and_CC Wales_NNP One_CD South_NNP Place_NNP London_NNP EC2M_NNP 2WG_NNP ,_, UK_NNP ACAMBIS_NNP US_NNP OPERATIONS_NNP Acambis_NNP Inc._NNP ._.
Bankers_NNP 38_CD Sidney_NNP Street_NNP Barclays_NNP Bank_NNP PLC_NNP Cambridge_NNP Corporate_NNP Banking_NNP Massachusetts_NNP 02139_CD ,_, USA_NNP PO_NNP Box_NNP 885_CD Telephone_NNP 1_CD 617 761 4200_CD Mortlock_NNP House_NNP Vision_NNP Park_NNP Berna_NNP Products_NNPS Corporation_NNP Histon_NNP 4216_CD Ponce_NNP fide_NN Leon_NNP Boulevard_NNP Cambridge_NNP CB49DE_NNP ,_, UK_NNP Coral_NNP Gables_NNP Florida_NNP 33146_CD ,_, USA_NNP Registrars_NNP Telephone_NNP 1_CD 800 392 9490_CD Capita_NNP Registrars_NNPS The_DT Registry_NNP SHAREHOLDER_NNP INFORMATION_NNP 34_CD Beckenham_NNP Road_NNP The_DT share_NN price_NN is_VBZ obtainable_JJ in_IN most_JJS UK_NNP and_CC US_NNP national_JJ newspapers_NNS Beckenham_NNP and_CC on_IN Acambis_NNP website_NN at_IN www_NN ._.
com_NN Kent_NNP BR34TU_NNP ,_, UK_NNP London_NNP Stock_NNP Exchange_NNP mnemonic_JJ ACM_NNP Auditors_NNS US_NNP NASDAQ_NNP National_NNP Market_NNP ticker_NN symbol_NN ACAM_NNP LLP_NNP Abacus_NNP House_NNP Reuters_NNP reference_NN ACM_NNP ._.
L_NNP Castle_NNP Park_NNP Cambridge_NNP CB30AN_NNP ,_, UK_NNP ANALYST_NNP COVERAGE_NNPS OF_IN ACAMBIS_NNP ABN_NNP Amro_NNP Cazenove_NNP CODE_NNP Securities_NNP Credit_NNP Suisse_NNP First_NNP Boston_NNP Deutsche_NNP Bank_NNP Evolution_NNP Beeson_NNP Gregory_NNP Goldman_NNP Sachs_NNP ING_NNP Barings_NNPS Jefferies_NNP KBC_NNP Peel_NNP Hunt_NNP Merrill_NNP Lynch_NNP Nomura_NNP Numis_NNP Panmure_NNP Gordon_NNP Teather_NNP &_CC Greenwood_NNP UBS_NNP Warburg_NNP Index_NNP ACAM2000_NNP 4_CD ,_, 11_CD ,_, 17_CD ,_, 22_CD Fixed_VBN asset_NN investments_NNS 53_CD ,_, 57_CD Staff_NN costs_NNS 54_CD Accounting_NN policies_NNS 50_CD Foreign_JJ currencies_NNS 52_CD ,_, 62_CD Statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS 46_CD Administrative_JJ costs_NNS 53_CD Stock_NNP 47_CD ,_, 59_CD ADR_NNP pricing_NN 25_CD ,_, 71_CD Goodwill_NNP 56_CD Stock_NNP options_NNS see_VBP Share_NN options_NNS Annual_JJ General_NNP Meeting_VBG 71_CD TM_NNP Substantial_NNP shareholdings_NNS 70_CD ARILVAX_NNP 4_CD ,_, 17_CD ,_, 23_CD Health_NNP and_CC safety_NN 21_CD ,_, 43_CD Summarised_NNP Group_NNP statements_NNS 69_CD Audit_NNP Committee_NNP 30_CD Auditors_NNS 45_CD ,_, 54_CD ,_, 72_CD Independent_NNP auditors_NNS report_VBP 45_CD Tangible_JJ fixed_JJ assets_NNS 57_CD Aventis_NNP Pasteur_NNP 17_CD Interest_NN 53_CD Taxation_NNP 46_CD ,_, 55_CD Internal_NNP control_NN 31_CD Total_JJ shareholder_NN return_NN 41_CD Balance_NN sheets_NNS 47_CD ,_, 48_CD Investments_NNPS 51_CD ,_, 57-58_CD Trade_NNP investments_NNS 58_CD Baxter_NNP 11_CD ,_, 17_CD ,_, 23_CD ,_, 48_CD Trading_NN results_NNS 24_CD Berna_NNP Biotech_NNP 17_CD Japanese_JJ encephalitis_NNS see_VBP ChimeriVax-JE_NNP Berna_NNP Products_NNPS Corporation_NNP 7_CD ,_, 9_CD ,_, 22_CD Joint_NNP venture_NN 61_CD Vaccine_NN market_NN 8-9_CD ,_, 16_CD Board_NNP of_IN Directors_NNS 14_CD ,_, 23_CD ,_, 26-27_CD ,_, 28_CD VIG_NNP C-VIG_NN 4_CD ,_, 11_CD ,_, 22_CD Leases_NNPS 52_CD Vivotif_NNP 4_CD ,_, 7_CD ,_, 17_CD ,_, 23_CD Cangene_NNP Corporation_NNP 11_CD ,_, 17_CD Canton_NNP see_VB Manufacturing_NNP Manufacturing_NNP 7_CD West_NNP Nile_NNP see_VBP ChimeriVax-West_NNP Nile_NNP Capital_NNP expenditure_NN 25_CD Memorandum_NNP and_CC Articles_NNPS of_IN Association_NNP 71_CD Cash_NN 46_CD MVA_NNP 2_CD ,_, 9_CD ,_, 17_CD ,_, 22_CD Acambis_NNP is_VBZ a_DT UK_NNP public_JJ limited_JJ company_NN Cash_NN flow_NN 49_CD ,_, 66_CD with_IN shares_NNS listed_VBN on_IN the_DT London_NNP Stock_NNP GOOD_NNP QUESTIONS_NNP Exchange_NNP and_CC ,_, in_IN the_DT form_NN of_IN American_JJ Chairmans_NNPS statement_NN 2-3_CD Nominations_NNPS Committee_NNP 31_CD 2_CD Chairmans_NNPS statement_NN Depositary_NNP Receipts_NNPS ,_, on_IN the_DT NASDAQ_NNP national_JJ Charitable_JJ donations_NNS 42_CD Notes_NNS to_TO Group_NNP financial_JJ statements_NNS 50-68_JJ market_NN ._.
This_DT is_VBZ the_DT Annual_JJ Report_NNP for_IN the_DT 4_CD Company_NN overview_NN ChimeriVax-Dengue_NNP 5_CD ,_, 17_CD ,_, 23_CD year_NN ended_VBD 31_CD December_NNP 2003_CD ._.
It_PRP contains_VBZ 6_CD Total_JJ integration_NN ChimeriVax-JE_NN 4_CD ,_, 17_CD ,_, 23_CD OFR_NNP 16-25_CD the_DT Annual_JJ Report_NNP and_CC Financial_NNP Statements_NNPS 8_CD The_DT vaccine_NN market_NN in_IN accordance_NN with_IN UK_NNP regulations_NNS ._.
The_DT ChimeriVax-West_NNP Nile_NNP 5_CD ,_, 8_CD ,_, 17_CD ,_, 23_CD Operating_NN review_NN 22-23_CD 10_CD The_DT smallpox_NN opportunity_NN Annual_JJ Report_NNP on_IN Form_NN 20-F_NN for_IN the_DT US_NNP C._NNP difficile_NN 5_CD ,_, 17_CD ,_, 23_CD Organisational_NNP structure_NN 48_CD 12_CD The_DT future_JJ Securities_NNPS and_CC Exchange_NNP Commission_NNP will_MD Company_NNP information_NN and_CC advisers_NNS 72_CD be_VB filed_VBN separately_RB ._.
References_NNS to_TO the_DT Group_NNP 14_CD Interview_NNP Abbreviations_NNPS used_VBD in_IN this_DT document_NN Corporate_JJ governance_NN statement_NN 28-33_CD Products_NNPS 16_CD ,_, 17_CD ,_, 22_CD and_CC Acambis_NNP throughout_IN this_DT document_NN ADR_NNP Accounting_NNP Principles_NNP Board_NNP relate_VBP to_TO Acambis_NNP plc_NN and_CC all_DT of_IN its_PRP$ subsidiary_NN Corporate_JJ social_JJ responsibility_NN 20-21_CD ,_, 42_CD Profit_NN and_CC loss_NN account_NN 46_CD BIA_NNP BioIndustry_NNP Association_NNP THE_DT STATEMENTS_NNS and_CC associated_VBN undertakings_NNS ._.
References_NNS BLA_NNP Biologics_NNPS License_NNP Application_NNP Creditors_NNPS 42_CD ,_, 47_CD ,_, 60_CD Pensions_NNS 35_CD ,_, 51_CD ,_, 67_CD 16_CD Operating_NN and_CC financial_JJ review_NN to_TO the_DT Company_NN are_VBP to_TO Acambis_NNP plc_NN ,_, the_DT BPC_NNP Berna_NNP Products_NNPS Corporation_NNP Political_NNP donations_NNS 42_CD 26_CD Board_NNP of_IN Directors_NNS ultimate_JJ holding_VBG company_NN ._.
CDC_NNP US_NNP Centers_NNPS for_IN Disease_NNP Control_NNP Debtors_NNP 47_CD ,_, 60_CD Post_NNP balance_NN sheet_NN events_NNS 43_CD ,_, 68_CD 28_CD Corporate_JJ governance_NN overview_NN and_CC Prevention_NNP Cautionary_NNP statement_NN regarding_VBG EITF_NNP Emerging_VBG Issues_NNS Task_NNP Force_NNP 30_CD Corporate_JJ governance_NN statement_NN Dengue_NNP see_VB ChimeriVax-Dengue_NNP forward-looking_JJ statements_NNS FASB_NNP Financial_NNP Accounting_NNP Standards_NNPS 34_CD Remuneration_NNP report_NN Directors_NNS interests_NNS 42_CD ,_, 55_CD R&D_NN 4_CD ,_, 42_CD Under_IN the_DT safe_JJ harbor_NN provisions_NNS of_IN the_DT Board_NNP 42_CD Directors_NNS report_NN Directors_NNS remuneration_VBP 34-41_CD ,_, 55_CD Registrars_NNPS 72_CD US_NNP Private_NNP Securities_NNP Litigation_NNP Reform_NNP Act_NNP FDA_NNP US_NNP Food_NNP and_CC Drug_NNP Administration_NNP 44_CD Directors_NNS responsibilities_NNS of_IN 1995_CD ,_, the_DT Company_NN cautions_VBZ investors_NNS Directors_NNS report_VBP 42_CD Related_JJ party_NN transactions_NNS 68_CD FIN_NNP FASB_NNP Interpretation_NNP Number_NNP that_IN any_DT forward-looking_JJ statements_NNS or_CC 45_CD Independent_JJ auditors_NNS report_VBP to_TO the_DT members_NNS of_IN Acambis_NNP plc_NN FRS_NNP Financial_NNP Reporting_NNP Standard_NNP Directors_NNS responsibilities_NNS 44_CD Remuneration_NNP Committee_NNP 30_CD projections_NNS made_VBN in_IN this_DT document_NN are_VBP IAS_NNP International_NNP Accounting_NNP Dividends_NNPS 42_CD ,_, 71_CD Remuneration_NNP report_NN 34-41_CD subject_NN to_TO risks_NNS and_CC uncertainties_NNS that_WDT may_MD Standard_NNP THE_DT NUMBERS_NNS cause_VB actual_JJ results_NNS to_TO differ_VB materially_RB Reserves_NNS 65-66_CD IFRS_NNP International_NNP Financial_NNP 46_CD Group_NNP profit_NN and_CC loss_NN account_NN from_IN those_DT projected_VBN ._.
These_DT forward-looking_JJ Reporting_NNP Standards_NNP Earnings_NNS per_IN share_NN 56_CD Risk_NN factors_NNS 19_CD ,_, 31-33_CD 46_CD Group_NNP statement_NN of_IN total_JJ recognized_VBN gains_NNS and_CC losses_NNS statements_NNS are_VBP based_VBN on_IN estimates_NNS and_CC IND_NNP Investigational_NNP New_NNP Drug_NNP Employees_NNP 21_CD ,_, 25_CD ,_, 42_CD assumptions_NNS made_VBN by_IN the_DT management_NN 47_CD Group_NNP balance_NN sheet_NN Application_NNP Environment_NNP 21_CD ,_, 43_CD Segmental_JJ information_NN 53_CD of_IN Acambis_NNP and_CC are_VBP believed_VBN to_TO be_VB reasonable_JJ ,_, R&D_NNP Research_NNP and_CC development_NN 48_CD Company_NN balance_NN sheet_NN though_RB are_VBP inherently_RB uncertain_JJ and_CC difficult_JJ Exceptional_JJ item_NN 53_CD Selected_VBN financial_JJ information_NN 69_CD SEC_NNP US_NNP Securities_NNPS and_CC Exchange_NNP 49_CD Group_NNP cash_NN flow_NN statement_NN to_TO predict_VB ._.
Actual_JJ results_NNS or_CC experience_NN could_MD Commission_NNP Exchange_NNP rate_NN information_NN 57_CD Share_NN capital_NN 64-65_CD 50_CD Notes_NNS to_TO Group_NNP financial_JJ statements_NNS differ_VBP materially_RB from_IN the_DT forward-looking_JJ SFAS_NNP Statement_NN of_IN Financial_NNP Executive_NNP Committee_NNP 31_CD Share_NN options_NNS 36-41_CD ,_, 52_CD statements_NNS ._.
Factors_NNS that_WDT may_MD affect_VB the_DT Accounting_NNP Standard_NNP Share_NNP pricing_NN 71_CD Groups_NNS operations_NNS are_VBP discussed_VBN in_IN the_DT UITF_NNP Urgent_NNP Issues_NNP Task_NNP Force_NNP GENERAL_NNP INFORMATION_NNP operating_NN and_CC financial_JJ review_NN and_CC the_DT UK_NNP GAAP_NNP United_NNP Kingdom_NNP generally_RB Financial_JJ commitments_NNS 67_CD Share_NN register_NN analysis_NN 70_CD 69_CD Summarised_NNP Group_NNP statements_NNS corporate_JJ governance_NN statement_NN contained_VBD accepted_VBN accounting_NN principles_NNS Financial_JJ instruments_NNS 22_CD Shareholder_NN information_NN 70-71_CD 70_CD Shareholder_NN information_NN within_IN this_DT Annual_JJ Report_NNP and_CC in_IN documents_NNS US_NNP GAAP_NNP United_NNP States_NNPS generally_RB accepted_VBN 72_CD Company_NN information_NN and_CC advisers_NNS Financial_NNP review_NN 24-25_CD Shareholders_NNS funds_NNS 66_CD as_IN filed_VBN with_IN the_DT US_NNP Securities_NNPS and_CC Exchange_NNP accounting_NN principles_NNS IBC_NNP Index_NNP WHO_WP World_NNP Health_NNP Organization_NNP Commission_NNP from_IN time_NN to_TO time_NN ._.
Financial_NNP systems_NNS 18_CD Smallpox_NNP vaccine_NN see_VBP ACAM2000_CD in_IN collaboration_NN with_IN Crescent_NNP Lodge_NNP ._.
Printed_NNP by_IN St_NNP Ives_NNP Westerham_NNP Press_NNP ACAMBIS_NNP PLC_NNP ANNUAL_NNP REPORT_NNP 2003_CD ACAMBIS_NNP PLC_NNP Peterhouse_NNP Technology_NNP Park_NNP 100_CD Fulbourn_NNP Road_NNP Cambridge_NNP CB1_NNP 9PT_NNP United_NNP Kingdom_NNP Telephone_NNP 44_CD 0_CD 1223 275 300_CD Good_JJ Fax_NNP 44_CD 0_CD 1223 416 300_CD Email_NNP acambis_VBZ acambis_NNS ._.
